Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

2019-04-01

Additional Metadata
Persistent URL	doi.org/10.1016/j.eururo.2018.12.019, hdl.handle.net/1765/116333
Journal	European Urology : Official Journal of the European Association of Urology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Zuiverloon, T., & Theodorescu, D. (2019). Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology : Official Journal of the European Association of Urology, 75(4), 694–694. doi:10.1016/j.eururo.2018.12.019

Publication